BiotechTube
AAX Biotech

AAX Biotech

Stockholm, Sweden· Est.
aaxbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.5M

Overview

AAX Biotech is a private, pre-revenue platform biotech company based in Stockholm, Sweden. It has developed two proprietary technology platforms, Seqitope® and Opti-mAb®, designed to improve the epitope mapping and molecular stability of antibody therapeutics, respectively. The company operates as a technology provider and potential drug discovery partner for larger pharmaceutical firms, aiming to accelerate and de-risk the development of antibody drugs. Its recent activities include securing investment and presenting at major industry conferences.

Antibodies

Technology Platform

Seqitope®: High-detail epitope mapping technology for antibody characterization. Opti-mAb®: Molecular stabilization platform for creating stable, non-aggregating scFv antibody fragments.

Funding History

1
Total raised:$2.5M
Seed$2.5M

Opportunities

The massive and growing monoclonal antibody therapeutics market creates a strong demand for enabling technologies that improve developability and de-risk R&D.
AAX's focused platforms address specific, high-value pain points in the drug development process, positioning it as a potential partner for numerous biopharma companies.
Successfully licensing its technologies could lead to significant milestone and royalty streams in the long term.

Risk Factors

The company's success is entirely dependent on external adoption of its platforms, facing significant business development and competition risks from other technology providers.
As a pre-revenue company, it relies on continued investment and partnership deals to fund operations, with revenue from royalties being distant and uncertain.
Technological disruption or failure to demonstrate clear superiority over existing methods could limit market traction.

Competitive Landscape

AAX operates in the competitive field of antibody discovery and optimization services. It faces competition from large CROs (e.g., Charles River, Lonza) offering epitope mapping and protein engineering, specialized biotech platforms (e.g., AbCellera, Biolojic Design), and in-house capabilities at large pharma. Its differentiation lies in the specific combination and claimed advantages of its Seqitope® and Opti-mAb® platforms.

More companies in Biologics / Biosimilars →More companies in Sweden →